Get the Stockscreener App
56.84
2.75%
-1.61
Palvella Therapeutics Inc stock is traded at $56.84, with a volume of 141.07K.
It is down -2.75% in the last 24 hours and up +31.54% over the past month.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
See More
Previous Close:
$58.45
Open:
$58.76
24h Volume:
141.07K
Relative Volume:
0.99
Market Cap:
$628.63M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+2.08%
1M Performance:
+31.54%
6M Performance:
+96.00%
1Y Performance:
+0.00%
1-Day Range:
$54.83
$59.31
1-Week Range:
$52.82
$61.48
52-Week Range:
$11.17
$61.48
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Name
Palvella Therapeutics Inc
Sector
Industry
Phone
(484) 253-1461
Address
125 STRAFFORD AVE, WAYNE
Compare PVLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
56.84 | 660.59M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-25 | Initiated | Oppenheimer | Outperform |
| Aug-06-25 | Initiated | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Apr-09-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-26-25 | Initiated | Stifel | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-20-25 | Initiated | Canaccord Genuity | Buy |
| Feb-05-25 | Initiated | TD Cowen | Buy |
| Dec-26-24 | Initiated | H.C. Wainwright | Buy |
| Dec-18-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-30-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-19 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Initiated | Jefferies | Buy |
| Jan-16-18 | Reiterated | H.C. Wainwright | Buy |
| May-30-17 | Initiated | Rodman & Renshaw | Buy |
| Aug-05-16 | Resumed | ROTH Capital | Buy |
| Aug-12-15 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-15 | Initiated | Oppenheimer | Outperform |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
View All
Palvella Therapeutics Inc Stock (PVLA) Latest News
Palvella Therapeutics (NASDAQ:PVLA) Sets New 52-Week HighWhat's Next? - MarketBeat
Multi asset correlation models including Palvella Therapeutics Inc.2025 Bull vs Bear & High Accuracy Trade Signal Alerts - Newser
Real time alert setup for Palvella Therapeutics Inc. performanceJuly 2025 Outlook & Comprehensive Market Scan Reports - Newser
Palvella Therapeutics Inc. stock outlook for YEARIndex Update & Weekly Top Stock Performers List - Newser
Applying sector rotation models to Palvella Therapeutics Inc.Analyst Downgrade & Pattern Based Trade Signal System - Newser
Palvella Therapeutics Inc. stock prediction for this weekMarket Trend Summary & Reliable Volume Spike Trade Alerts - Newser
Is Palvella Therapeutics Inc. forming a bottoming basePortfolio Risk Summary & Low Risk Entry Point Tips - Newser
Statistical indicators supporting Palvella Therapeutics Inc.’s strength2025 Price Momentum & Scalable Portfolio Growth Ideas - Newser
Intraday pattern recognizer results for Palvella Therapeutics Inc.July 2025 Retail & Weekly Momentum Picks - Newser
What the charts say about Palvella Therapeutics Inc. todayJuly 2025 Decliners & Weekly Breakout Watchlists - Newser
Custom watchlist performance reports with Palvella Therapeutics Inc.Portfolio Update Summary & Stepwise Entry/Exit Trade Alerts - Newser
Palvella Therapeutics Inc. stock momentum explained2025 Price Momentum & Breakout Confirmation Alerts - Newser
Is Palvella Therapeutics Inc. stock ready for a breakoutTreasury Yields & Daily Chart Pattern Signal Reports - Newser
Comparing Palvella Therapeutics Inc. in custom built stock radars2025 Short Interest & Accurate Buy Signal Notifications - Newser
Real time breakdown of Palvella Therapeutics Inc. stock performanceQuarterly Earnings Summary & Weekly Watchlist for Hot Stocks - Newser
News impact scoring models applied to Palvella Therapeutics IncJuly 2025 Selloffs & AI Forecast for Swing Trade Picks - Newser
Key metrics from Palvella Therapeutics Inc.’s quarterly dataWeekly Stock Report & Daily Oversold Bounce Ideas - Newser
How hedge fund analytics apply to Palvella Therapeutics Inc. stockQuarterly Profit Summary & AI Enhanced Trading Signals - Newser
Can you recover from losses in Palvella Therapeutics Inc.July 2025 Analyst Calls & Safe Capital Allocation Plans - Newser
is palvella therapeutics inc. forming a bottoming baseTreasury Yields & Fast Moving Stock Trade Plans - Newser
Palvella Therapeutics Names David W. Osborne, Ph.D. as Chief Innovation Officer - MSN
Quantitative breakdown of Palvella Therapeutics Inc. recent moveTrade Risk Assessment & Long Hold Capital Preservation Plans - Newser
Strategies to average down on Palvella Therapeutics Inc.July 2025 Market Mood & Breakout Confirmation Alerts - Newser
Applying Elliott Wave Theory to Palvella Therapeutics Inc.Weekly Profit Summary & Risk Managed Investment Strategies - Newser
Using flow based indicators on Palvella Therapeutics Inc.2025 Sector Review & Low Risk High Win Rate Picks - Newser
Palvella Therapeutics Inc.’s volatility index tracking explainedJuly 2025 Recap & Capital Protection Trade Alerts - Newser
Is Palvella Therapeutics Inc. showing signs of accumulationCEO Change & Weekly Momentum Picks - Newser
How to track smart money flows in Palvella Therapeutics Inc.July 2025 WrapUp & Real-Time Volume Trigger Notifications - Newser
Cantor Fitzgerald Sticks to Its Buy Rating for Palvella Therapeutics (PVLA) - The Globe and Mail
Oppenheimer Initiates Palvella Therapeutics at Outperform - MarketScreener
Using RSI to spot recovery in Palvella Therapeutics Inc.2025 Sector Review & Growth Focused Stock Pick Reports - Newser
Will Palvella Therapeutics Inc. stock recover after recent dropJuly 2025 Trends & Verified Momentum Watchlists - Newser
Is Palvella Therapeutics Inc. trending in predictive chart modelsEarnings Trend Report & Growth Focused Stock Pick Reports - Newser
Palvella Therapeutics Inc Stock (PVLA) Financials Data
There is no financial data for Palvella Therapeutics Inc (PVLA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):